GenKyoTex S.A.

France-based biotech GenKyoTex SA will begin designing a Phase III trial for its lead compound GKT831 after the selective inhibitor of NOX-1 and NOX-4 produced encouraging short-term effects on pati

The progression of investigational products through a series of increasingly more sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for c

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer

New At The Helm Company Changes ALMEIDA , Joe To: Baxter International Inc. , Chmn. & CEO (Jan. 2016) From: Covidien PLC, Pres. & CEO Phone: 847-948-2000 AVILA , Manny To: IlluminOss Medica